Market Place
Sourcing Support
Gilead’s Livdelzi Shows Sustained Efficacy in Biliary Cholangitis
15 Nov 2024 //
BUSINESSWIRE
FDA approval of Livdelzi, Gilead launches an inflammatory drug for first time
16 Aug 2024 //
FIERCE PHARMA
Orsini Now Dispensing Livdelzi (seladelpar), for Treatment of Rare Liver Disease
15 Aug 2024 //
PR NEWSWIRE
Gilead shows $4.3B liver drug improves outcomes out to 2 years
05 Jun 2024 //
FIERCE BIOTECH
Gilead: Seladelpar Sustained Efficacy/Safety Profile In PBC
05 Jun 2024 //
BUSINESSWIRE
Gilead liver disease med still delivers ahead of FDA verdict
20 May 2024 //
FIERCE BIOTECH
Seladelpar Shows Liver, Itch Improvements In PBC
18 May 2024 //
BUSINESSWIRE
The New England Journal Publishes Positive Phase 3 of CymaBay`s Seladelpar
21 Feb 2024 //
PR NEWSWIRE
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
13 Feb 2024 //
PRESS RELEASE
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar
12 Feb 2024 //
PR NEWSWIRE
Published Data Showes Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement
03 Jan 2024 //
PR NEWSWIRE
CymaBay Submits NDA for Seladelpar for Treatment of Primary Biliary Cholangitis
15 Dec 2023 //
PR NEWSWIRE
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results
13 Nov 2023 //
PR NEWSWIRE
CymaBay Announces Publication of Two-year Safety Results of Seladelpar
01 Nov 2023 //
GLOBENEWSWIRE
Seladelpar Granted Breakthrough Therapy Designation for Biliary Cholangitis
23 Oct 2023 //
GLOBENEWSWIRE
CymaBay™s Ph 3 Data Evaluating Seladelpar for Biliary Cholangitis to be Featured
18 Oct 2023 //
GLOBENEWSWIRE
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar
21 Sep 2023 //
GLOBENEWSWIRE
CymaBay`s Seladelpar Achieves Significance in Phase 3 in Biliary Cholangitis
07 Sep 2023 //
PR NEWSWIRE
CymaBay Initiates Phase 3 Placebo-Controlled, Randomized Study of Seladelpar
10 Aug 2023 //
PR NEWSWIRE
CymaBay Announces Publication of Results FromENHANCE, Ph 3 Study of Seladelpar
21 Apr 2023 //
GLOBENEWSWIRE
CymaBay Tx to Publish Results From 52-Week Phase 2 Study of Seladelpar in PBC
04 Apr 2022 //
GLOBENEWSWIRE
Bon Secours Liver Institute of Richmond Participating in RESPONSE Study
03 Feb 2022 //
GLOBENEWSWIRE
Liver Institute NW Participating in RESPONSE, a Global Phase 3 Research Study
01 Feb 2022 //
GLOBENEWSWIRE
CymaBay Announces Presentations at International Liver Congress 2021
09 Jun 2021 //
GLOBENEWSWIRE
CymaBay Therapeutics to Present Data from its Ph2 Study of Seladelpar
01 Oct 2020 //
GLOBENEWSWIRE
FDA lifts hold on CymaBay’s NASH drug, but the company may still leave the ailing field
25 Jul 2020 //
ENDPTS
Genfit goes to China with a deal worth up to $228M for NASH drug
24 Jun 2019 //
ENDPTS
NASH contender CymaBay runs into trouble as mid-stage data disappoint
11 Jun 2019 //
ENDPTS
CymaBay Therapeutics` Seladelpar FDA Breakthrough Therapy Designated
15 Feb 2019 //
GLOBENEWSWIRE
